Alphamab Oncology (HKG:9966)
13.70
+0.61 (4.66%)
Sep 30, 2025, 4:08 PM HKT
Alphamab Oncology Revenue
Alphamab Oncology had revenue of 319.44M CNY in the half year ending June 30, 2025, with 134.08% growth. This brings the company's revenue in the last twelve months to 785.96M, up 207.17% year-over-year. In the year 2024, Alphamab Oncology had annual revenue of 640.08M with 192.58% growth.
Revenue (ttm)
785.96M CNY
Revenue Growth
+207.17%
P/S Ratio
15.45
Revenue / Employee
1.87M CNY
Employees
420
Market Cap
13.31B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 640.08M | 421.31M | 192.58% |
Dec 31, 2023 | 218.77M | 51.93M | 31.12% |
Dec 31, 2022 | 166.85M | 20.82M | 14.26% |
Dec 31, 2021 | 146.02M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines AG | 35.81B |
Hansoh Pharmaceutical Group Company | 14.45B |
JD Health International | 71.34B |
Innovent Biologics | 12.52B |
WuXi Biologics | 21.98B |
Sino Biopharmaceutical | 33.49B |
Akeso | 2.75B |
Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |